ArriVent BioPharma, Inc. (NASDAQ:AVBP) appears in 119 institutional 13F filings for the quarter ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 4,401,083 | 295,048 | 7.19% | $101,532,985.00 |
| INFINITUM ASSET MANAGEMENT, LLC | 31 Mar, 2026 | 4,148,923 | 25,000 | 0.61% | $95,715,654.00 |
| INFINITUM ASSET MANAGEMENT, LLC | 31 Mar, 2026 | 4,123,923 | 255,000 | 6.59% | $82,973,331.00 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 4,106,035 | 402,583 | 10.87% | $82,613,424.00 |
| HHLR ADVISORS, LTD. | 31 Mar, 2026 | 3,929,117 | -555,555 | -12.39% | $79,053,834.00 |
| HHLR ADVISORS, LTD. | 31 Mar, 2026 | 3,929,117 | 0 | 0.00% | $90,644,729.00 |
| FMR LLC | 31 Mar, 2026 | 3,703,572 | 296,023 | 8.69% | $74,515,872.00 |
| ORBIMED ADVISORS LLC | 31 Mar, 2026 | 3,027,328 | 0 | 0.00% | $69,840,457.00 |
| ORBIMED ADVISORS LLC | 31 Mar, 2026 | 3,027,328 | 0 | 0.00% | $60,909,839.00 |
| FMR LLC | 31 Mar, 2026 | 3,016,132 | -687,440 | -18.56% | $69,582,163.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 2,530,301 | 157,463 | 6.64% | $58,374,044.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 2,372,838 | 326,700 | 15.97% | $47,741,500.00 |
| Octagon Capital Advisors LP | 31 Mar, 2026 | 1,971,054 | 0 | 0.00% | $45,472,216.00 |
| Octagon Capital Advisors LP | 31 Mar, 2026 | 1,971,054 | 0 | 0.00% | $39,657,606.00 |
| Novo Holdings A/S | 31 Mar, 2026 | 1,942,142 | 0 | 0.00% | $39,075,897.00 |
| Novo Holdings A/S | 31 Mar, 2026 | 1,942,142 | 0 | 0.00% | $44,805,216.00 |
| VANGUARD GROUP INC | 31 Mar, 2026 | 1,869,266 | -160,265 | -7.90% | $37,609,632.00 |
| Sofinnova Investments, Inc. | 31 Mar, 2026 | 1,696,752 | 0 | 0.00% | $34,138,650.00 |
| Sofinnova Investments, Inc. | 31 Mar, 2026 | 1,696,752 | 0 | 0.00% | $39,144,069.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 1,528,893 | 1,528,893 | 0.00% | $35,271,562.00 |